Hunan Warrant Pharmaceutical Co.,Ltd (SHA:688799)
China · Delayed Price · Currency is CNY 58.21
+0.01 (0.02%)
Apr 29, 2026, 3:00 PM CST
SHA:688799 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,493 | 1,504 | 1,399 | 1,403 | 1,273 | 1,135 |
Other Revenue | - | - | 14.06 | 29.33 | 19.2 | 11.95 |
| 1,493 | 1,504 | 1,413 | 1,433 | 1,293 | 1,147 | |
Revenue Growth (YoY) | 8.45% | 6.46% | -1.39% | 10.84% | 12.74% | 20.61% |
Cost of Revenue | 612.44 | 597.4 | 547.62 | 512.15 | 421.91 | 319.33 |
Gross Profit | 880.11 | 906.83 | 865.33 | 920.64 | 870.75 | 827.26 |
Selling, General & Admin | 602.19 | 617.76 | 547.26 | 595.34 | 595.97 | 585.96 |
Research & Development | 124.26 | 129.85 | 158.33 | 103.18 | 88.67 | 70.06 |
Other Operating Expenses | -3.84 | -6.42 | 20.3 | 17.68 | 16.9 | 14.05 |
Operating Expenses | 722.61 | 741.19 | 726.21 | 717.67 | 703.76 | 671.38 |
Operating Income | 157.49 | 165.64 | 139.12 | 202.97 | 166.99 | 155.89 |
Interest Expense | - | - | -0.02 | - | - | - |
Interest & Investment Income | 83.8 | 84.34 | 16.84 | 16.02 | 15.21 | 5.87 |
Currency Exchange Gain (Loss) | - | - | 0.42 | 0.01 | 0.53 | -0.03 |
Other Non Operating Income (Expenses) | -0.36 | -0.25 | -1.1 | -0.24 | -0.24 | -0.51 |
EBT Excluding Unusual Items | 240.93 | 249.73 | 155.27 | 218.76 | 182.5 | 161.21 |
Gain (Loss) on Sale of Investments | -0.57 | - | -24.31 | - | - | - |
Gain (Loss) on Sale of Assets | -0 | -0 | -0.03 | -0.48 | -0.89 | -0.39 |
Asset Writedown | -12.81 | -8.83 | - | - | - | - |
Legal Settlements | - | - | - | -5.28 | - | -1.95 |
Other Unusual Items | - | - | 30.75 | 16.87 | 13.36 | 21.16 |
Pretax Income | 227.55 | 240.9 | 161.68 | 229.88 | 194.96 | 180.03 |
Income Tax Expense | 9.82 | 12.8 | 22.92 | 36.84 | 21.57 | 19.27 |
Earnings From Continuing Operations | 217.73 | 228.1 | 138.76 | 193.04 | 173.39 | 160.76 |
Minority Interest in Earnings | 6.21 | 10.18 | 25.56 | 18.28 | 9.42 | - |
Net Income | 223.94 | 238.28 | 164.32 | 211.32 | 182.8 | 160.76 |
Net Income to Common | 223.94 | 238.28 | 164.32 | 211.32 | 182.8 | 160.76 |
Net Income Growth | 53.94% | 45.01% | -22.24% | 15.60% | 13.71% | 10.85% |
Shares Outstanding (Basic) | 132 | 132 | 131 | 131 | 131 | 112 |
Shares Outstanding (Diluted) | 135 | 135 | 131 | 131 | 131 | 112 |
Shares Change (YoY) | 2.38% | 2.41% | -0.03% | 0.19% | 17.21% | 13.60% |
EPS (Basic) | 1.70 | 1.81 | 1.25 | 1.61 | 1.39 | 1.44 |
EPS (Diluted) | 1.66 | 1.77 | 1.25 | 1.61 | 1.39 | 1.44 |
EPS Growth | 50.36% | 41.60% | -22.22% | 15.38% | -2.98% | -2.43% |
Free Cash Flow | -278.02 | -220.12 | -91.65 | 108.68 | 23.8 | 22.63 |
Free Cash Flow Per Share | -2.06 | -1.64 | -0.70 | 0.83 | 0.18 | 0.20 |
Dividend Per Share | - | - | 0.429 | 0.643 | 0.643 | 0.500 |
Dividend Growth | - | - | -33.33% | - | 28.58% | - |
Gross Margin | 58.97% | 60.28% | 61.24% | 64.25% | 67.36% | 72.15% |
Operating Margin | 10.55% | 11.01% | 9.85% | 14.17% | 12.92% | 13.60% |
Profit Margin | 15.00% | 15.84% | 11.63% | 14.75% | 14.14% | 14.02% |
Free Cash Flow Margin | -18.63% | -14.63% | -6.49% | 7.58% | 1.84% | 1.97% |
EBITDA | 229.08 | 236.69 | 208.03 | 263.99 | 215.78 | 190.11 |
EBITDA Margin | 15.35% | 15.73% | 14.72% | 18.43% | 16.69% | 16.58% |
D&A For EBITDA | 71.59 | 71.05 | 68.9 | 61.02 | 48.79 | 34.22 |
EBIT | 157.49 | 165.64 | 139.12 | 202.97 | 166.99 | 155.89 |
EBIT Margin | 10.55% | 11.01% | 9.85% | 14.17% | 12.92% | 13.60% |
Effective Tax Rate | 4.31% | 5.31% | 14.17% | 16.03% | 11.06% | 10.70% |
Revenue as Reported | - | - | 1,413 | 1,433 | 1,293 | 1,147 |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.